Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Here’s a drug project to watch: Louisiana officially unveiled a proposal this week in which the state would pay drug companies fixed prices over several years for “unlimited access” to hepatitis C drugs for Medicaid and prison populations.
The big picture: Louisiana is calling it a “subscription payment model” — kind of like Netflix. Except instead of nonstop streaming, Louisiana gets as many hepatitis C treatments as it needs. Louisiana thinks it can save money and lives, while locking in revenue for drug companies.
What they’re saying: Gilead Sciences, the dominant maker of a hepatitis C cure, appears to be on board.
- “I think there is a pretty good meeting of the minds between Gilead and the state of Louisiana,” a Gilead executive told NPR last month. “Ideally, we’d have something in place this year.”
- Comments about the model are due by Aug. 24.